Trials
3 active
7 in total · 4 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Newnorm is a 20% human normal immunoglobulin for SC infusion.”In the company’s words, NCT04640142 on ClinicalTrials.gov
- Tested for
- Primary Immune Deficiency, Pediatric Chronic Inflammatory Demyelinating Polyneuropathy, Hypogammaglobulinemia, Autoimmune Conditions, Rheumatic Conditions, Infections
- Main trialPhase 3
- “Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with primary immunodeficiency diseases”In the company’s words, NCT04640142 on ClinicalTrials.gov
- Other names
- NewGam · Newnorm
Other drugs for Primary Immune Deficiency
- IVIG-VImmuneVirchow Group · Phase 3
- DonidalorsenIonis Pharmaceuticals, Inc. · Phase 3
- Kedrion IVIG 10%Kedrion S.p.A. · Phase 3
- NavenibartAstria Therapeutics, Inc. · Phase 3
- DeucrictibantPharvaris Netherlands B.V. · Phase 3
- ADX-324ADARx Pharmaceuticals, Inc. · Phase 3
Coming up3
- NovPhase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2028Phase 3 trial completes · ClinicalTrials.gov
- Dec 2029Phase 3 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovCompletion date moved: 2026-09 to 2026-11 · ClinicalTrials.gov NCT04640142
Trials7
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Nov 2026 | Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases | |
| Phase 3Recruiting | 31 Dec 2028 | Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients | |
| Phase 3Recruiting | Dec 2029 | Supporting Weak Immune System During Autoimmune Therapy: Testing Panzyga to Prevent Infections | |
| Phase 4Terminated | 19 Sep 2023 | Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP) | |
| Phase 3Completed | 5 Sep 2019 | Study to Evaluate Safety and Efficacy of Three Different Dosages of NewGam in Patients With Chronic Inflammatory Demyelinating Poly (Radiculo) Neuropathy | |
| Phase 3Completed | 27 Aug 2024 | Phase III Study To Compare The Effect of Panzyga Versus Placebo in Patients With Pediatric Acute-onset Neuropsychiatric Syndrome (PANS/PANDAS) | |
| Phase 3Completed | 19 Sep 2025 | Double-blind, Randomized, Placebo-controlled, Prospective Phase III Study Evaluating Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients With Chronic Lymphocytic Leukemia ("PRO-SID" Study) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026